Invention Grant
- Patent Title: ERAP1-derived peptide and use thereof
-
Application No.: US14235666Application Date: 2012-07-27
-
Publication No.: US09725490B2Publication Date: 2017-08-08
- Inventor: Toyomasa Katagiri , Takuya Tsunoda
- Applicant: Toyomasa Katagiri , Takuya Tsunoda
- Applicant Address: JP Tokushima JP Kanagawa
- Assignee: TOKUSHIMA UNIVERSITY,ONCOTHERAPY SCIENCE, INC.
- Current Assignee: TOKUSHIMA UNIVERSITY,ONCOTHERAPY SCIENCE, INC.
- Current Assignee Address: JP Tokushima JP Kanagawa
- Agency: Rankin, Hill & Clark LLP
- Priority: JP2011-167171 20110729
- International Application: PCT/JP2012/069131 WO 20120727
- International Announcement: WO2013/018690 WO 20130207
- Main IPC: C07K7/06
- IPC: C07K7/06 ; C07K7/04 ; C07K14/47 ; G01N33/50 ; G01N33/574 ; C12N9/48 ; A61K31/138 ; A61K38/17 ; A61K38/00
Abstract:
Provided is a novel cancer-treating agent which can be used as a novel choice for the treatment of cancer. Specifically provided are: a peptide that inhibits binding of ERAP1 polypeptide to PHB2 polypeptide, which comprises a binding site of the ERAP1 polypeptide to the PHB2 polypeptide, and a pharmaceutical composition comprising the peptide. In addition, provided is a method for screening a drug candidate for treating and/or preventing cancer using inhibition of the binding of the ERAP1 polypeptide to PP1α polypeptide, PKA polypeptide or PKB polypeptide as an index.
Public/Granted literature
- US20140162952A1 ERAP1-DERIVED PEPTIDE AND USE THEREOF Public/Granted day:2014-06-12
Information query
